REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Ortho-hydroxybenzoic Acid (i.e., Salicyclic Acid) Or Derivative Doai > 9,10-seco- Cyclopentanohydrophenanthrene Ring System (e.g., Vitamin D, Etc.) Doai 9,10-seco- Cyclopentanohydrophenanthrene Ring System (e.g., Vitamin D, Etc.) Doai9,10-seco- Cyclopentanohydrophenanthrene Ring System (e.g., Vitamin D, Etc.) Doai patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027120 - Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes Methods of treating MDS, or ameliorating a symptom thereof, are disclosed. Specific methods encompass the administration of one or more vitamin D compounds, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with one or more additional active agents. Other methods include intermittent ... 01/11/07 - 20070010500 - Prevention of ovarian cancer by administration of a vitamin d compound The present invention relates to methods for preventing the development of epithelial ovarian cancer by administering a Vitamin D compound in an amount capable of increasing apoptosis in non-neoplastic ovarian epithelial cells of the female subject. ... 01/04/07 - 20070004688 - Pharmaceutical compositions comprising active vitamin d compounds Disclosed are pharmaceutical compositions comprising an active vitamin D compound in emulsion pre-concentrate formulations, as well as emulsions and sub-micron droplet emulsions produced therefrom. The compositions comprise a lipophilic phase component, one or more surfactants, and an active vitamin D compound. The compositions may optionally further comprise a hydrophilic phase ... 12/28/06 - 20060293291 - 2-propylidene-19-nor-vitamin d compounds 2-propylidene-19-nor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by high bone calcium mobilization activity and high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment and prophylaxis of diseases where bone ... 11/30/06 - 20060270640 - Method of preventing, medicating, and/or treating hypocalcemia of domestic mammal Specifically, the present invention provides a method of administrating a vitamin D derivative to prevent, cure and/or treat hypocalcemia, characterized in that a vitamin D derivative, especially, 1α-hydroxyvitamin D3 and/or 1.25-dihydroxyvitamin D3 is transvaginally administered to a domestic mammal. ... 11/23/06 - 20060264410 - 19,26,27-trinor-1alpha,25-dihydroxyvitamin d3 compounds Compounds of formula 1 are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups, and R1 and R2 have the definitions provided herein. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions. ... 11/16/06 - 20060258630 - Method for the prevention and treatment of uveitis The invention provides 1,3-di-acylated vitamin D3 analogs of cholecalciferol, substituted at carbon-20 with methyl or cyclopropyl wherein carbon-16 is a single or double bond, and carbon-23 is a single, double, or triple bond. Various alkyl or haloalkyl substitutions are incorporated at carbon-25. The invention provides pharmaceutically acceptable esters, salts, and ... 10/26/06 - 20060241090 - Use of 2-methylene-19-nor-20(s)-1alpha,25dihydroxyvitamin d3 to increase the life expectancy of human beings This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3. Administration of this compound increases the life expectancy of human beings, especially elderly human beings. In particular, it increases the survival rate of females lacking estrogen, especially post-menopausal females, and reduces mortality resulting from spontaneous development of malignant tumors in both males ... 09/28/06 - 20060217354 - Crystals of a vitamin d derivative and a method for the preparation thereof crystals of a vitamin D derivative which are obtained by purifying a crude or preliminarily purified product of the vitamin D derivative through a reverse phase chromatography and then crystallizing the purified derivative from an organic solvent; novel compounds which are formed during the synthesis of a vitamin D derivative ... 09/28/06 - 20060217353 - 24-sulfoximine vitamin d3 compounds The present invention provides novel sulfoximine compounds, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the compounds of the invention are useful for treating diseases which benefit from a modulation of the levels of 1α,25-dihydroxy vitamin D3, for example, cell-proliferative disorders. ... 09/21/06 - 20060211661 - 24 hydroxyvitamin d, analogs and uses thereof The invention provides 24-hydroxyvitamin D compounds and methods for their use in the treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders. ... 08/24/06 - 20060189586 - Pharmaceutical compositions comprising active vitamin d compounds Disclosed are pharmaceutical compositions comprising an active vitamin D compound in emulsion pre-concentrate formulations, as well as emulsions and sub-micron droplet emulsions produced therefrom. The compositions comprise a lipophilic phase component, one or more surfactants, and an active vitamin D compound. The compositions may optionally further comprise a hydrophilic phase ... 08/24/06 - 20060189585 - Dosage and method for attaining beneficial levels of vitamin d3 The present invention provides for: (a) an oral dosage of vitamin D3 for humans sufficient to maintain a serum level above a minimally sufficient level and below a toxic level when administered according to a schedule of at least one dosage a week up to at least one dosage a ... 08/17/06 - 20060183722 - Formulation for lipophilic agents The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same. ... 08/17/06 - 20060183721 - 2-methylene-19-nor-(20s-24epi)-1alpha,25-dihydroxyvitamin d2 Compounds of formula I are provided where X1, X2, and X3 are independently selected from H or hydroxy protecting groups. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions. ... 08/10/06 - 20060178351 - Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents The present invention relates to a method for treating, ameliorating, or preventing immune-mediated disorders in an animal by administering to the animal active vitamin D compounds or mimics thereof The invention further relates to a method for treating, ameliorating, or preventing immune-mediated disorders in an animal by administering to the ... 08/10/06 - 20060178350 - 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes The present invention relates to 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, compositions which comprise said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]-decanes, and methods for treating diseases, illnesses, and the like with said 7-(2-cyclohexylidene-ethylidene)-spiro[4.5]decanes. ... 07/27/06 - 20060166949 - Vitamin d analogues, compositions comprising said analogues and their use and prodrugs and stereo isomeric forms thereof are provided together with their use in therapy, and their use in the manufacture of medicaments. ... 07/27/06 - 20060166948 - Compositions comprising vitamin k for treating or preventing age-related stiffening of arteries Vitamin K is effective in counteracting the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) ... 07/20/06 - 20060160779 - 2,2-di-substituted 1alpha,25-dihydroxy-19-norvitamin d derivative A novel 2,2-di-substituted 19-norvitamin D derivative. It is a compound represented by the general formula (I) wherein R1 and R2 are the same or different and each represents hydroxy and A represents hydrogen, or an unsubstituted linear or branched alkyl. ... 07/13/06 - 20060154902 - Shortening of hospital stay and improving survival in patients with chronic kidney disease Formulations containing a Vitamin D compound or analog, such as paricalcitol (Zemplar™) are useful for shortening hospital stays in chronic kidney disease patients with or without hyperparathyroidism. Also disclosed are methods of shortening hospital stays for chronic kidney disease patients with or without hyperparathyroidism, and methods for determining reduction length ... 07/06/06 - 20060148769 - (20s)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin d3 and their uses This invention discloses (20S)-1α-hydroxy-2α-methyl-19-nor-vitamin D3 and (20S)-1α-hydroxy-2β-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well ... 07/06/06 - 20060148768 - Vitamin d3 lactone derivatives [wherein R1 refers to hydrogen atom, C1-C6 alkyl group optionally substituted with hydrogen group or C1-C6 alkoxy group optionally substituted with hydroxyl group, R2a and R2b refer to hydrogen atom, C1-C10 alkyl group optionally substituted with hydroxyl group, C6-C10 aryl group optionally substituted with hydroxyl group or C7-C12 aralkyl group ... 06/22/06 - 20060135493 - Use of 2-methylene-19-nor-20(s)-1alpha,25-dihydroxyvitamin d3 to increase bone strength This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3. This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic agent for the treatment of diseases where bone formation is desired, particularly osteoporosis. This compound also exhibits pronounced activity in arresting ... 06/22/06 - 20060135492 - Use of 2-methylene-19-nor-20(s)-1alpha,25-dihydroxyvitamin d3 to increase bone strength This invention provides pharmaceutical-uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3. This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic agent for the treatment of diseases where bone formation is desired, particularly osteoporosis. This compound also exhibits pronounced activity in arresting the ... 06/22/06 - 20060135491 - Vitamin d3 analog useful for the treatment of osteoporosis The present invention relates to the vitamin D3 analog (1R,3R)-5-{(E)-(2R, 5R)-2-[2-(4-hydroxy-4-methylpentyl)-spiro[4.5]dec-7-ylidene]-ethylidene}-cyclohexane-1,3-diol which is useful in the treatment of osteoporosis. ... 06/08/06 - 20060122157 - 2-methylene-18,19-dinor-1alpha-hydroxy-homopregnacalciferol and its uses This invention discloses 2-methylene-18,19-dinor-vitamin D analogs, and specifically 2-methylene-18,19-dinor-1α-hydroxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as ... 05/25/06 - 20060111330 - 17,20(e)-dehydro vitamin d analogs and their uses This invention discloses 17,20(E)-dehydro vitamin D analogs, and specifically 17(E)-1α,25-dihydroxy-17(20)-dehydro-2-methylene-19-nor-vitamin D3 and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as ... 05/18/06 - 20060106003 - Combination of a macrolide t-cell immunomodulator and a calciferol for the treatment of skin diseases or of inflammatory bowel disease Synergistic combinations of a macrolide T-cell immunomodulator or immunosuppressant such as 33-epichloro-33-desoxyascomycin and a calciferol or tacalcitol are provided, which are useful in particular in the treatment of dermatological diseases such as atopic dermatitis, acen and psoriasis or of inflammatory bowel disease (IBD). ... 04/13/06 - 20060079490 - Method of treatment of type i diabetes A method of delaying the onset or reducing the severity of diabetes in a human patient is disclosed. In one embodiment, the invention comprises the step of orally administering to the human patient an effective amount of a vitamin D compound such as the onset of diabetes or diabetes symptoms ... 03/09/06 - 20060052350 - Crystalline forms of 1,24(s)-dihydroxy vitamin d2 Provided are novel crystalline forms of 1,24-(S)-dihydroxy vitamin D2, including hydrates and solvates, and methods for making them. Also provided are pharmaceutical and nutraceutical compositions containing the novel crystalline forms. ... 02/09/06 - 20060030549 - Paricalcitol(zemplar) capsule controls secondary hyperparathyroidism (shpt) in ckd stage 5 patients Oral paricalcitol for sustained reduction of parathyroid hormone in dialysis patients. ... 02/02/06 - 20060025388 - Compositions and methods relating to novel compounds and targets thereof The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine derivatives and methods of using benzodiazepine derivatives as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell ... 01/26/06 - 20060019933 - Process for preparing stabilized vitamin d This invention is related to a process for preparing a stabilized form of vitamin D which comprises the steps of: a) dissolving vitamin D in a solution that contains water and at least one surfactant to produce a mixture; b) spraying the mixture onto an inert carrier to produce a ... 01/12/06 - 20060009426 - Pharmaceutical compositions comprising calcitriol and a clobetasol propionate Topically applicable pharmaceutical gel, cream, lotion, solution or ointment compositions contain synergistically effective amounts of a) calcitriol and b) clobetasol propionate, formulated into a topically applicable, pharmaceutically acceptable medium therefor, and are useful for the treatment of such dermatological afflictions or conditions as psoriasis, atopic dermatitis, contact dermatitis and seborrhoeic ... 01/12/06 - 20060009425 - Oral formulations of paricalcitol The present invention relates to oral formulations comprising paricalcitol that are available in a variety of different dosage forms that are bioequivalent to one another. ... 01/05/06 - 20060003973 - Use of 2alpha-methyl-19-nor-20(s)-1alpha,25-dihydroxyvitamin d3 to increase bone strength This invention provides pharmaceutical uses for 2α-methyl-19-nor-20(S)-1α,25-dihydroxyvitamin D3. This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic agent for the treatment of diseases where bone formation is desired, particularly osteoporosis. This compound also exhibits pronounced activity in arresting ... 12/22/05 - 20050282789 - 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity which allows their in vivo administration for the treatment of metabolic bone ... 12/22/05 - 20050282788 - Pharmaceutical compositions comprising silicones and two solubilized active principles Topically applicable, anhydrous and physically/chemically stable pharmaceutical compositions useful for the treatment of disorders of the skin, notably psoriasis, contain a silicone agent; a therapeutically effect amount of a compound A selected from the group consisting of vitamin D or derivative thereof, solubilized in a solvent therefor; and a therapeutically ... 11/24/05 - 20050261256 - Treatment of icu-associated hypocalcemia with vitamin d compounds The present invention relates to a method of improving intensive care unit (ICU)-associated hypocalcemia in a mammal by the administration of a vitamin D compound, or other compounds exhibiting vitamin D-like activity, to the mammal for a sufficient period of time to improve or restore the serum calcium levels of ... 11/17/05 - 20050256092 - Antipsoriatic agent A therapeutic agent for psoriasis, comprising 2β-(3-hydroxypropyloxy)-1α,25-dihydroxyvitamin D3 as an active ingredient, is provided by the present invention. ... 10/27/05 - 20050239756 - Methods of treating various vitamin d metabolism conditions with 1alpha-hydroxyvitamin d2 The present invention provides a method of increasing or maintaining blood concentrations of 1,25-dihydroxyvitamin D in a patient by administering an amount of 1α-hydroxyvitamin D2. The invention also provides a method of concurrently lowering or maintaining plasma intact parathyroid hormone levels, increasing or maintaining serum calcium levels, maintaining serum phosphorous ... 10/13/05 - 20050227951 - Verification of translation The invention relates to new vitamin D derivatives of general formula (I), process for their production, intermediate products of the process as well as the use for production of pharmaceutical agents. ... 10/13/05 - 20050227950 - 2-alkylidene-18,19-dinor-vitamin d compounds 2-alkylidene-18,19-dinor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by low bone calcium mobilization activity and high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment and prophylaxis of diseases where bone ... 09/22/05 - 20050209203 - Use of vitamin ds or vitamin d analogs to treat cardiovascular disease Disclosed are pharmaceutical compositions containing Vitamin D receptor activators or Vitamin D analogs to treat, prevent or inhibit vascular disease. The pharmaceutical compositions may also include ACE inhibitors or other agents. Also disclosed are methods of reducing PAI-1 expression by administering effective amounts of Vitamin D receptor activators or Vitamin ... 09/15/05 - 20050203071 - Use of carbon-2-modified-19-nor-vitamin d analogs to induce the formation of new bone It has been discovered that the 2-carbon-modified derivatives of 1α,25-dihydroxyvitamin D3 specifically stimulate osteoblasts to form new bone. The ability of the 2-carbon-modified vitamin D analogs to stimulate new bone formation suggest that these compounds can be used where synthesis of new bone is required. Thus, these compounds can be ... 09/01/05 - 20050192256 - Methods of using vitamin d compounds in the treatment of patients undergoing hemodialysis The subject invention relates to methods of using Vitamin D compounds such as, for example, paricalcitol and calcitriol, in the treatment of patients undergoing hemodialysis. More specifically, administration of Vitamin D compounds appears to reduce the incidence of hospitalization, length of days spent in the hospital and morbidity in treated ... 09/01/05 - 20050192255 - Use of vitamin ds or vitamin d analogs to treat cardiovascular disease Disclosed are pharmaceutical compositions containing Vitamin D receptor activators or Vitamin D analogs to treat, prevent or inhibit vascular disease. The pharmaceutical compositions may also include ACE inhibitors or other agents. Also disclosed are methods of reducing PAI-1 expression by administering effective amounts of Vitamin D receptor activators or Vitamin ... 08/25/05 - 20050187201 - Use of 2-methylene-19-nor-20(s)-1alpha,25-dihydroxyvitamin d3 for the prophylaxis of bone diseases This invention provides pharmaceutical uses for 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3. This compound is characterized by high bone calcium mobilization activity demonstrating preferential activity on bone. This results in a novel therapeutic agent for the treatment and prophylaxis of diseases where bone formation is desired, particularly osteoporosis. This compound also increases both breaking ... 08/18/05 - 20050182035 - Method of locking 1beta-oh of vitamin d compounds in axial orientation A method of modifying or altering the structure of a 1α-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents the 1α-hydroxyl in the axial orientation. This is accomplished by either locking the A-ring chair conformation ... 08/18/05 - 20050182034 - Method of locking 1alpha-oh of vitamin d compounds in axial orientation A method of modifying or altering the structure of a 1α-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents the 1α-hydroxyl in the axial orientation. This is accomplished by either locking the A-ring chair conformation ... 08/18/05 - 20050182033 - Vitamin d receptor antagonists and their use in treating asthma Various compounds such as those having the formula I and XIV where the variables have the values described herein antagonize the vitamin D receptor and are useful in treating conditions such as asthma and in preparing medicaments for use in antagonizing the vitamin D receptor or treating conditions such as ... 08/18/05 - 20050182032 - Vitamin d3 lactam derivative In the formula, R1 is a C2-C10 alkyl group, or a C7-Cl5 aralkyl group whose aromatic ring is optionally substituted with a C1-C6 alkyl group, a C1-C6 alkoxyl group, a hydroxyl group, a halogen atom or a trifluoromethyl group; and R2 is a C1-C10 alkyl group, or a C7-C15 aralkyl ... 07/28/05 - 20050164995 - Method of locking 1alpha-oh of vitamin d compounds in axial orientation A method of modifying or altering the structure of a 1α-hydroxylated vitamin D compound to increase its biological activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents the 1α-hydroxyl in the axial orientation. This is accomplished by either locking the A-ring chair conformation ... 07/21/05 - 20050159397 - (20s)-1alpha-hydroxy-2alpha-methyl and 2beta-methyl-19-nor-vitamin d3 and their uses This invention discloses (20S)-1α-hydroxy-2α-methyl-19-nor-vitamin D3 and (20S)-1α-hydroxy-2β-methyl-19-nor-vitamin D3 and pharmaceutical uses therefor. These compounds exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well ... 07/07/05 - 20050148558 - Stabilized hydroxyvitamin d The invention provides a stabilized 1α-hydroxyvitamin D (“SHVD”) which is particularly well suited for pharmaceutical formulations. ... 07/07/05 - 20050148557 - Use of vitamin ds to treat kidney disease Disclosed are compositions containing a VDRA/Vitamin D analog to treat or prevent kidney disease, including chronic kidney disease. The present invention also relates to methods of treating kidney disease by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a VDRA/Vitamin D analog. Compositions according to ... 06/30/05 - 20050143358 - Methods for reducing body fat using vitamin d compounds A treatment for obesity and overweight comprises administering a vitamin D analog. The analog effectively inhibits an increase in body fat to animals at risk and decreases the basal fat content of animals. The treatment has a positive effect on the lean body component such that while there is an ... 06/30/05 - 20050143357 - Vitamin d upregulated protein 1 (vdup-) methods and uses thereof A method for selecting a compound or a composition of matter for treatment of hyperproliferative disorders of the prostate in a mammal by administering the compound or the composition to a mammal (in vivo) or to a prostate cell culture (in vitro) and assessing the effect of the compound or ... 06/09/05 - 20050124591 - Use of vitamin ds to treat kidney disease Disclosed are compositions containing a VDRA/Vitamin D analog to treat or prevent kidney disease, including chronic kidney disease. The present invention also relates to methods of treating kidney disease by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a VDRA/Vitamin D analog. Compositions according to ... 06/02/05 - 20050119242 - Vitamin d analogs for obesity prevention and treatment Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and/or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D3 or 1α,25-dihydroxyvitamin D2 or a pharmaceutical composition that includes such an analog to a subject in need thereof. The analog ... 06/02/05 - 20050119241 - Preparation of 24 alkyl analogs of cholecalciferol and non-racemic compounds Disclosed is a process for the preparation of 24-alkyl analogs of cholecalcyferol of Formula 1 having a (5E) or (5Z) configuration, wherein X represents a hydrogen atom, a hydroxy group or an OR1 group, where R1, R2 and R3 may be the same or different and represent groups suitable for ... 06/02/05 - 20050119240 - 1-methyl-20-epi-vitamin d derivative A vitamin D derivative which has a methyl group in the 1-position and has an epi form in the 20-position. The vitamin D derivative is represented by the general formula (1): wherein R represents linear or branched alkyl optionally substituted by hydroxy. ... ### FreshPatents.com Support |